Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2019 Filed Jul 2, 2019 21:05 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $123.17 | $98,536.00 |
DisclosureSEC source: 0001127602-19-023656 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,423 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:05 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-023656 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:05 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $123.17 | $98,536.00 |
DisclosureSEC source: 0001127602-19-023656 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,023 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-022170 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,223 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 847 | $118.44 | $100,318.68 |
DisclosureSEC source: 0001127602-19-022170 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 150,617 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $118.44 | $391,681.08 |
DisclosureSEC source: 0001127602-19-022170 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:39 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-022170 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,204 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,211 | $118.32 | $616,575.94 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.87 to 118.79. The price reported above reflects the weighted average sale price. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 1,440 | $117.56 | $169,286.40 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,548 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.84 to $117.82. The price reported above reflects the weighted average sale price. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-020711 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,838 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $114.01 | $91,208.00 |
DisclosureSEC source: 0001127602-19-020711 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $114.01 | $91,208.00 |
DisclosureSEC source: 0001127602-19-020711 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,023 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-020711 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,835 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $114.01 | $497,881.67 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 17:46 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 239 | $114.12 | $27,274.68 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 06/01/2017. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 15:46 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $112.34 | $337,020.00 |
DisclosureSEC source: 0001127602-19-020402 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,514 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 124.66 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 23,629 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · derivative · entry 9 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 23,629 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 9,628 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · derivative · entry 8 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 9,628 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 11,085 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · derivative · entry 7 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,628 Underlying: ResMed Common Stock · 11,085 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 23,629 | $114.00 | $2,693,706.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 6 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 23,629 | $52.02 | $1,229,180.58 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 5 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 9,628 | $114.00 | $1,097,592.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 4 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 9,628 | $51.25 | $493,435.00 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 3 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 11,085 | $113.44 | $1,257,426.98 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $113.44 to $113.45. The price reported above reflects the weighted average sale price. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:37 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 11,085 | $51.25 | $568,106.25 |
DisclosureSEC source: 0001127602-19-020022 · form4.xml · nonDerivative · entry 1 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-018678 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,530 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 893 | $111.35 | $99,435.55 |
DisclosureSEC source: 0001127602-19-018678 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 151,464 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $111.35 | $368,234.45 |
DisclosureSEC source: 0001127602-19-018678 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-018678 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 117.072 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,855 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F5 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 260 | $110.25 | $28,664.22 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.17 to $110.29. The price reported above reflects the weighted average sale price. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,391 | $109.70 | $701,086.31 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,597 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.17 to $110.16. The price reported above reflects the weighted average sale price. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 54.834 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,202 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $112.58 | $491,636.86 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,122 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 119.99 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-017358 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,638 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $104.51 | $83,608.00 |
DisclosureSEC source: 0001127602-19-017358 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,857 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $104.51 | $83,608.00 |
DisclosureSEC source: 0001127602-19-017358 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,657 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2019 Filed May 3, 2019 23:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-017358 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 30, 2019 Filed May 1, 2019 22:13 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $102.98 | $308,940.00 |
DisclosureSEC source: 0001127602-19-016793 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-015601 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,837 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 978 | $102.29 | $100,039.62 |
DisclosureSEC source: 0001127602-19-015601 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 152,357 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $102.29 | $338,273.03 |
DisclosureSEC source: 0001127602-19-015601 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,297 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-015601 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,506 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.